The mainstream media, giddy with excitement about the new Omicron variant, has announced that its friends at the Food and Drug Administration will fast-track brand new vaccines in order to address what they perceive to be a pending crisis, the Wall Street Journal reported.
With the new variant allegedly tearing through Europe and now entering the United States, Big Pharma has decided to create a designer vaccine to specifically target Omicron.
Eager to help out its Big Pharma comrades, the FDA then committed to ramming through the vaccines with less oversight than ever before.
The FDA’s updated methods would immediately clear previously authorized consumer goods, like the COVID vaccine, that are being tweaked to address Omicron.
The bureaucracy would demand less data than required for the initial authorization, a person familiar with the matter said.
But according to that same source, the FDA has yet to decide how far the efficacy of current vaccines would have to drop in order to justify the large-scale experimentation.
Earlier this week, Pfizer Chief Executive Albert Bourla said, “I think the results could be, which we don’t know yet, that the vaccines protect less.”
Jesse Goodman, a professor of medicine at Georgetown University and a former FDA chief scientist, justified the FDA’s to consider using the American people as lab rats.
“It’s a way of looking at the strength of the body’s response, that gives you answers more quickly,” she said.
The Wall Street Journal, as expected, took a financial approach to the new vaccines, suggesting that investors might increase their investments in Big Pharma.
“The more subtle impact of Omicron is to shift investors’ probabilities away from expecting the virus will disappear and more toward anticipating virus presence as the new normal,” Bernstein analyst Ronny Gal wrote. “This will help the vaccine/therapies manufacturers.”
